Top-News

Akcea Therapeutics News

Aktie
WKN:  A2DUYE ISIN:  US00972L1070 US-Symbol:  AKCA
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
101,60 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 16.10.2020

Akcea Therapeutics News

30.10.20 - PR Newswire
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire
12.10.20 - PR Newswire
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire
26.09.20 - PR Newswire
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, ...
25.09.20 - PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta S
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ ...
25.09.20 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations PR Newswire
22.09.20 - PR Newswire
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm PR Newswire
11.09.20 - PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigations PR Newswire
10.09.20 - PR Newswire
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial Corporation, Cancer Genetics, Inc., Proteostasis Therapeutics, Inc., Rosetta Stone Inc., and Yintech Investment Holdings L
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Broadway Financial ...
10.09.20 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - PRNB, BLDR, AKCA, YIN PR ...
05.09.20 - PR Newswire
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm PR Newswire
01.09.20 - PR Newswire
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA PR Newswire
01.09.20 - PR Newswire
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price? PR Newswire
29.08.20 - PR Newswire
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen ...
29.08.20 - PR Newswire
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Positive Phase 2 Clinical Data of AKCEA-​APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-​breaking presentation show patients with hypertriglyceridemia experienced ...
24.08.20 - PR Newswire
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-​breaking presentation to focus on efficacy and safety data ...
18.08.20 - PR Newswire
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Akcea and Ionis to Present Phase 2 Results of AKCEA-​APOCIII-L(Rx) in Late-​Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and ...
13.08.20 - PR Newswire
Akcea gibt neue Preisgestaltung und Kostenerstattung für WAYLIVRA® (Volanesorsen) in Deutschland bekannt
Akcea gibt neue Preisgestaltung und Kostenerstattung für WAYLIVRA® (Volanesorsen) in Deutschland bekannt PR Newswire
13.08.20 - PR Newswire
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia ...
04.08.20 - PR Newswire
Akcea Reports Financial Results and Highlights for Second Quarter 2020
Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-​Over-Year Achieved Pricing and ...
22.07.20 - PR Newswire
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy TEGSEDI is the first ...

Newssuche

Videos

newspaper
08:45 Uhr -3,13%
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »